All In Biotech

Drug Trial Radar · NCT05133830

Linerixibat and Obeticholic Acid Drug Interaction Study in Healthy Adult Participants

A Two-part, Phase 1, Open-label, Randomized, Parallel-arm, Fixed Sequence, Drug-drug Interaction Study to Investigate the Effect of Linerixibat on Plasma Concentrations of Obeticholic Acid and Conjugates in Healthy Adult Participants

Last checked: Nov 20, 2026Latest source record: Nov 8, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

52

Actual

Start

Nov 23, 2021

Primary completion

May 31, 2022

Study completion May 31, 2022

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Nov 24, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study aims to investigate the effect of linerixibat on plasma concentrations of obeticholic acid (OCA) and its conjugates in healthy adult participants to inform the potential for drug interaction with coadministration of linerixibat and OCA.

Conditions

  • Pruritus

Interventions

  • Obeticholic acidDrug

    OCA will be administered

  • LinerixibatDrug

    Linerixibat will be administered

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Average trough concentration (Ctrough) in plasma for total-OCA at steady stateTime frame: Days 35 to 38

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Baltimore, Maryland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.